Dudley Robert Michael has filed 6 insider transactions across 1 company since May 2023.
Most recent transaction: a purchase of 98000 shares of Transcode Therapeutics, Inc. ($RNAZ) on September 28, 2023.
Activity breakdown: 5 open-market purchases and 0 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sept. 28, 2023 | Transcode Therapeutics, Inc. | $RNAZ | Dudley Robert Michael | Chief Executive Officer | P | Common Stock | 98000 | $0.51 | 180,262.0000 | 30,494 | 119.13% | 100.00% |
| June 20, 2023 | Transcode Therapeutics, Inc. | $RNAZ | Dudley Robert Michael | Chief Executive Officer | P | Common Stock | 6607 | $2.55 | 70,262.0000 | 18,593 | 10.38% | 35.54% |
| June 21, 2023 | Transcode Therapeutics, Inc. | $RNAZ | Dudley Robert Michael | Chief Executive Officer | P | Common Stock | 12000 | $2.65 | 82,262.0000 | 18,593 | 17.08% | 64.54% |
| June 9, 2023 | Transcode Therapeutics, Inc. | $RNAZ | Dudley Robert Michael | Chief Executive Officer | P | Common Stock | 19000 | $2.76 | 61,155.0000 | 18,593 | 45.07% | 100.00% |
| June 9, 2023 | Transcode Therapeutics, Inc. | $RNAZ | Dudley Robert Michael | Chief Executive Officer | P | Common Stock | 19000 | $2.76 | 912,114.0000 | 18,593 | 2.13% | 100.00% |
| May 19, 2023 | Transcode Therapeutics, Inc. | $RNAZ | Dudley Robert Michael | Chief Executive Officer | A | Stock Option (right to buy) | 735000 | $0.00 | 735,000.0000 | 18,593 | 9999.99% | 100.00% |